Current therapies for HBV infection generate a sterilizing or functional cure in a very small fraction of treated individuals. Thus, many new therapeutic approaches are under preclinical and clinical development. Here I will show how insights into these new therapies and HBV biology can be gained by mathematically modeling some of the accumulating experimental data. For example, by blocking new infections with the entry inhibitor Myrculdex B (Myr-B), one can gain insight into the lifespan of HBV-infected hepatocytes. Analysis of viral load decay after initiation of Myr-B therapy suggests that there may be heterogeneity in the lifespan of HBV infected cells in vivo, with some infected cells living much longer than others and producing less virus. As another example, I will show how new mathematical models are able to provide quantitative insights into the effects of monotherapy using a capsid inhibitor (CI) and combination therapies of a CI with a nucleic acid analog. Lastly, I will discuss how modeling is providing new estimates of the plasma half-life of HbsAg (as well as that of other species such as HBV DNA and ALT) which may inform therapeutic progress and duration of therapy need to achieve a functional cure.